Genomics and Bioinformatics Group web site development and maintenance

我们正在成功地维护和扩展基于web的发现工具，重点是CellMiner和CellMinerCDB。我们的CellMiner“NCI-60分析工具”部分仍然是药物基因组学整合，研究和发现的重要资源。它目前是四个工具的宿主，i)“细胞系特征”，ii)相互关联，iii)模式比较，iv)“药物与基因变异/异构体变异”，所有这些工具都旨在减少科学家整合分子和药理学数据所需的时间。在本节中，我们将继续升级软件和数据库。我们目前提供了在任何大规模细胞数据库中最具包容性的分子和最大的化合物活性数据集。CellMiner的数据和工具为癌症患者的合理药物发现、应用和个性化治疗创造了重大机遇。由于许多类型的分子改变可以影响治疗结果，基因组和药理学设施（GPF）以这样一种方式管理和整合分子和药理学数据，以增强理解，并促进可测试假设的产生。因此，GPF既提供对高吞吐量数据的访问，又提供有助于挖掘、理解和利用这些数据的软件资源。由于DTP药物数据库包含未开发的化合物和药物，它在识别潜在的新药和提高对已有药物的理解方面仍然是一个无与伦比的资源。NCI-60是迄今为止最全面的哺乳动物细胞面板。CellMiner CDB扩展了这种方法，包括允许用户随意挖掘和集成的附加数据库。目前，我们的Discover和CellMiner网站每月有来自90个国家的8400名个人用户。它过去和现在都在引领着转化性的发现。

We are successfully maintaining and expanding the Discover web-based tools, with emphasis on CellMiner and the CellMinerCDB's. Our CellMiner "NCI-60 Analysis Tools" section remains a significant resource for pharmacogenomic integration, research, and discovery. It is currently the host for four tools, i) "Cell line signature", ii) Cross-correlation", iii) Pattern comparison", and iv) "Drug vs gene variant/isoforms variant", all of which are designed to reduce the time required by the scientist to integrate molecular and pharmacological data. We continue to upgrade both the software and databases in this section. We currently provide the most inclusive set of molecular and largest compound activity data among any of the large-scale cellular databases. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of therapy, the Genomic and Pharmacolgy Facility (GPF) manages and integrates molecular and pharmacological data in such a way that enhances understanding, and facilitates the generation of testable hypotheses. The GPF thus both provides access to high throughput data, and provides software resources that facilitate the mining, understanding, and exploitation of that data. As the DTP drug database contains both unexplored compounds and drugs, it remains an unmatched resource both for recognition of potential novel drugs, and improving understanding of pre-existing ones. The NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. CellMiner CDB expands this approach to include addition databases allowing the user to mine and integrate at will. Currently our Discover and CellMiner sites have 8,400 individual users from 90 countries per month. It has in the past and currently continues to lead to translational discoveries.